BB Biotech Q3 2026 Interim Report — Now available

BB Biotech Q3 2026 Interim Report — Now available

Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech — Positive Q3 returns; portfolio recycling accelerates

The Edison report on BB Biotech highlights our positive Q3 performance, accelerated portfolio activity and clinical progress across the portfolio, with a look ahead to upcoming Q4 milestones.
28.10.2026